Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma
- 25 April 2020
- journal article
- letter
- Published by Informa UK Limited in Leukemia & Lymphoma
- Vol. 61 (8), 2003-2007
- https://doi.org/10.1080/10428194.2020.1753044
Abstract
(2020). Characterizing the belinostat response in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Leukemia & Lymphoma. Ahead of Print.Keywords
This publication has 15 references indexed in Scilit:
- Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphomaHematological Oncology, 2016
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) StudyJournal of Clinical Oncology, 2015
- Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective reviewTherapeutic Advances in Hematology, 2015
- The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T‐cell lymphomaBritish Journal of Haematology, 2015
- Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma RegistryBlood, 2014
- Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin LymphomasSeminars in Hematology, 2014
- Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parametersBlood, 2012
- IDH2 mutations are frequent in angioimmunoblastic T-cell lymphomaBlood, 2012
- Phase 2 trial of romidepsin in patients with peripheral T-cell lymphomaBlood, 2011
- WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview.2010